Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This Phase 2/3 study is a multi-portion design to confirm that the chosen formulation and dosing regimen of CoVLP has an acceptable immunogenicity and safety profile. The Phase 3 portion is an event-driven, randomized, observer blinded, placebo-controlled design that will evaluate the efficacy and safety of the CoVLP formulation compared to placebo. Subjects will be followed for safety and immunogenicity for a period of 12 months after the last vaccination.
Epistemonikos ID: 9330fecc789f94af6cd83bc815d4a893ab7b752e
First added on: Nov 20, 2020